Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.
Channels (Austin)
; 7(1): 17-22, 2013 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-23221478
ABSTRACT
Heart failure is becoming a global epidemic. It exerts a staggering toll on quality of life, and substantial medical and economic impact. In a pre-clinical model of cardiac hypertrophy and heart failure, we were able to overcome loss of heart function by administering the TRPV1 antagonist BCTC (4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide). The results presented here identify TRPV1 antagonists as new treatment options for cardiac hypertrophy and heart failure.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazinas
/
Piridinas
/
Cardiomegalia
/
Canais de Cátion TRPV
/
Insuficiência Cardíaca
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article